Skip to main content

Advertisement

Table 1 Patients’ characteristics at baseline (N = 51)

From: Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial

Patients’ characteristics Median %
Median age, years (range) 57 (27–78)  
Sex   
 Male 36 70.6
 Female 15 29.4
ECOG score   
 0-1 48 94.1
 2 3 5.9
Primary tumor site   
 stomach 33 64.7
 Gastroesophageal junction 18 35.3
Type of gastric cancer(assessed by central laboratory)   
 Intestinal type 34 66.7
 Diffuse type 10 19.6
 Mix type 7 13.7
HER2 status   
 IHC 3+ 38 74.5
 IHC 2+,Dual SISH + 13 25.5
HER2/CEP17 ratio by dc-SISH   
 2.01–5.0 15 29.4
 5.1–50 32 62.7
 Failed 4 7.8
Histology   
 Well-moderately differentiated 24 47.1
 Poorly differentiated (signet ring cell, undetermined) 27 52.9
Extent of disease   
 Locally advanced 7 13.7
 Metastatic 44 86.3
Metastastic disease   
 Liver 31 60.8
 Lung 13 25.5
 Bone 2 3.9
 Ovarian 1 1.9
 Lymphnodes 44 86.3
Prior gastrectomy   
 No 45 88.2
 Yes 6 11.8
Prior adjuvant chemotherapy   
 No 50 98.1
 Yes 1 1.9